NasdaqGM:RYTMBiotechs
Rhythm Pharmaceuticals (RYTM) Stock Rises As HO Demand Meets Loss Pressure
Rhythm Pharmaceuticals stock closed up 2.9% at US$105.78, a sharp intraday vote of confidence after a choppy month that left the shares down about 7% over 30 days. The move came as investors digested a Q2 report that paired rapid revenue expansion with continued losses, a familiar trade off in high growth biotech.
The headline this quarter is clear. Global net product sales reached US$71.3 million, powered by early demand for IMCIVREE in acquired hypothalamic obesity, while the company still...